WuXi Advanced Therapies

What WuXi Advanced Therapies does

WuXi Advanced Therapies is a pure-play cell and gene therapy Contract Development and Manufacturing Organization (CDMO) operating through the Minaris Advanced Therapies brand. Founded in 2004 and headquartered in Philadelphia with 251–500 employees, the business offers end-to-end services spanning process development, cGMP manufacturing, and commercial supply for cell therapies (CAR-T, NK, HSC, iPSC) and viral vector–based gene therapies (lentiviral and AAV). It also operates an integrated Laboratory Testing Service Platform providing biosafety testing, viral clearance, potency assays, lot release, cell line characterization, and ICH-compliant stability programs for biologics, viral vaccines, and advanced therapies. The company differentiates through proprietary process IP — notably TESSA for AAV production, XOFLX lentiviral packaging producer cell lines, and SnapFast modular plasmids — and supports clients across five global manufacturing and testing facilities in the US, Europe and Asia, with multi-jurisdictional GMP certifications from the FDA, EMA, TGA, PMDA, and relevant ISO standards.

The business model is a fee-for-service CDMO contract structure: revenue is generated through development, manufacturing, and testing programs priced per project, milestone, or commercial batch rather than product sales or royalties. Go-to-market is direct enterprise sales to biotech and pharmaceutical sponsors of advanced therapies, anchored by long-cycle engagements that combine process development, tech transfer, GMP manufacturing, and analytical testing under a single supplier. Pricing is not publicly disclosed. The unit was identified as one of the key competitors profiled in the global AAV process development services market alongside Thermo Fisher Scientific, Sartorius AG, and Charles River Laboratories, a market estimated at $3.8B in 2025 and projected to reach $8.9B by 2034.

Name

WuXi Advanced Therapies

Website

https://advancedtherapies.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

WuXi Advanced Therapies is a Philadelphia-based, pure-play cell and gene therapy CDMO offering process development, cGMP manufacturing, and biosafety testing across five global facilities in the US, Europe, and Asia for biotech and pharma sponsors.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Cell Therapy CDMO (HLAGABAD), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Cell therapy manufacturing
• Gene therapy CDMO
• Viral vector production
• Biosafety testing services
• Cell line development

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Core offering

WuXi Advanced Therapies (operating as Minaris) is a pure-play cell and gene therapy CDMO that delivers end-to-end contract development, cGMP manufacturing, and commercial supply for cell therapies (CAR-T, NK, HSC, iPSC) and gene therapies (AAV and lentiviral vectors), supported by an integrated advanced testing services platform covering biosafety, viral clearance, potency, stability, lot release, and cell line characterization. The portfolio is anchored by proprietary enabling technologies — TESSA for AAV production, XOFLX lentiviral packaging cell lines, and SnapFast modular plasmids — that improve yield, scalability, and cost-efficiency for gene therapy manufacturing.

Product overview

Minaris (formerly known in part through WuXi Advanced Therapies ecosystem) operates as a pure-play cell and gene therapy CDMO offering integrated process development, cGMP manufacturing, and advanced testing services. The portfolio combines proprietary technologies (TESSA for AAV production, XOFLX for lentiviral vectors) with comprehensive service offerings including plasmid engineering, cell banking, analytical development, biosafety testing, viral clearance, lot release, and stability studies. The company maintains five global manufacturing and testing facilities across the US, Europe, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell & Gene Therapy CDMO Services End-to-end contract development and manufacturing services for cell and gene therapies, including process development, cGMP manufacturing, and commercial supply for cell therapies (CAR-T, NK, HSC, iPSC) and viral vector-based gene therapies.
• Viral Vector Services Comprehensive lentiviral and AAV vector services spanning plasmid design, process development, and cGMP manufacturing for gene therapy programs.
• Cell Therapy GMP Manufacturing cGMP manufacturing services for cell therapies including CAR-T, NK, HSC, and iPSC programs, from clinical through commercial supply.
• Cell Banking Services cGMP cell banking services for cell and gene therapy and biologics, supporting Master, Working, and End-of-Production Cell Banks.
• TESSA AAV Production Technology Proprietary AAV production technology that delivers high-titer, high-quality adeno-associated virus for gene therapy manufacturing, available as an enabling platform within the company's CDMO services.
• XOFLX Lentiviral Packaging Producer Cell Lines Proprietary high-yield lentiviral vector (LVV) producer cell line platform enabling simplified, scalable, and cost-efficient LVV manufacturing.
• SnapFast Modular Plasmids Modular plasmid system enabling easy, reliable insertion for creating custom constructs across various expression platforms, supporting gene therapy and cell therapy manufacturing.
• Biosafety Testing Laboratory (Minaris Advanced Testing) Integrated GMP-compliant testing laboratory offering biosafety, viral clearance, potency, stability, lot release, and cell line characterization services for mAbs, viral vaccines, and advanced therapies.
• Biosafety Testing GMP-compliant sterility, mycoplasma, endotoxin, adventitious agent, and replication-competent virus testing for cell and gene therapy products.
• Viral Clearance Services Viral clearance study design and validation aligned with ICH Q5A(R2), FDA, EMA, and WHO guidelines for biologics and advanced therapies.
• Potency Testing Custom assay design and validation including cell-based functional studies, reporter gene assays, ELISA, PCR, and transduction efficiency tests for cell and gene therapy products.
• Lot Release Testing Comprehensive GMP testing panel for therapy lot release including sterility, identity, potency, purity, and residuals testing for cell and gene therapy products.
• Stability Studies ICH Q1-compliant stability programs including long-term, real-time, accelerated, and ongoing studies for biologic and advanced therapy modalities.
• Analytical Development Assay design, optimization, and validation services across the full product lifecycle from early-phase methods to commercial readiness for biologics and advanced therapies.
• Cell Line Characterization Regulatory-compliant characterization of Master, Working, and End-of-Production Cell Banks for biologics and advanced therapies.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific (Patheon/Cobra Biologics): Named alongside WuXi in the AAV process development competitive landscape. Offers viral vector and cell therapy CDMO services as part of its much broader pharma services portfolio, providing deep capital and global reach that smaller CGT pure-plays must compete against.
• Sartorius AG: Profiled as a co-competitor in AAV process development services. Combines bioprocessing equipment with CDMO services, giving it a vertically integrated upstream/downstream position that competes with WuXi's plasmid-to-GMP workflow.
• Catalent (Novo Holdings): Major cell therapy CDMO with deep CAR-T and gene therapy manufacturing relationships. Now owned by Novo Holdings, Catalent competes directly for autologous/allogeneic cell therapy programs and viral vector work, at substantially larger scale.
• Lonza Group: One of the world's largest biologics CDMOs with a growing cell and gene therapy franchise. Competes with WuXi for viral vector and cell therapy manufacturing contracts at global scale, with multi-site GMP capacity across Europe and the US.

Direct peers

• Charles River Laboratories: Directly named as a co-competitor in the AAV process development market. Provides viral vector CDMO, cell therapy services, and biosafety testing — overlapping closely with WuXi's CGT CDMO + integrated testing offering.
• AGC Biologics: Mid-scale CDMO with dedicated cell and gene therapy services including viral vector manufacturing. Closely comparable in scope to WuXi/Minaris — both target CGT-focused biotech sponsors with integrated process development, GMP manufacturing, and analytical services.
• Forge Biologics: Pure-play AAV-focused CDMO offering end-to-end gene therapy development and manufacturing. Competes head-to-head with WuXi's viral vector franchise and similarly emphasizes scalable, high-yield AAV production platforms.
• National Resilience: Technology-focused CDMO investing heavily in viral vector and cell therapy capacity. Targets the same CGT sponsor base as WuXi/Minaris with an integrated manufacturing + analytics model, backed by significant venture funding.

Regional players

• Cell and Gene Therapy Catapult: UK-based CGT manufacturing center offering process development and GMP manufacturing for cell and gene therapies. Operates a comparable CDMO-plus-testing model in a single geography, competing for European CGT programs.
• Yposkesi: French CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy. Directly comparable in modality and service scope but operates primarily in Europe, providing regional competition for European CGT sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Adv_Therapies
• LinkedInlinkedin.com/company/wuxi-advanced-therapies

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi Advanced Therapies